Aphria (NYSE:APHA) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
This is a summary of recent ratings and price targets for Aphria and USANA Health Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|USANA Health Sciences||0||0||1||0||3.00|
Aphria currently has a consensus target price of $8.83, indicating a potential upside of 90.68%. Given Aphria’s higher probable upside, equities research analysts plainly believe Aphria is more favorable than USANA Health Sciences.
Insider and Institutional Ownership
9.6% of Aphria shares are owned by institutional investors. Comparatively, 55.5% of USANA Health Sciences shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Aphria and USANA Health Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|USANA Health Sciences||10.35%||32.87%||22.28%|
Volatility & Risk
Aphria has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Valuation & Earnings
This table compares Aphria and USANA Health Sciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aphria||$179.29 million||7.44||-$12.48 million||($0.11)||-42.09|
|USANA Health Sciences||$1.06 billion||1.49||$100.53 million||$4.41||17.01|
USANA Health Sciences has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences beats Aphria on 8 of the 13 factors compared between the two stocks.
Aphria Company Profile
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensébeautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.